<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695613</url>
  </required_header>
  <id_info>
    <org_study_id>17300539</org_study_id>
    <nct_id>NCT04695613</nct_id>
  </id_info>
  <brief_title>Shivering Control After Percutaneous Nephrolithotomy</brief_title>
  <official_title>Amino Acids Versus Magnesium Sulphate Infusion in Controlling Postoperative Shivering</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is comparing the effect of amino acid versus magnesium sulfate infusion on&#xD;
      postoperative shivering in patients undergoing elective percutaneous nephrolithotomy surgery&#xD;
      under general anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A written informed consent was taken from the patients. Patients were assigned randomly to&#xD;
      two groups (40 subjects each) to be anesthetized and infused with either an iv amino acid&#xD;
      starting just before and during anesthesia (group A) or an iv magnesium sulphate starting&#xD;
      just before and during anesthesia (group M) in the perioperative period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2021</start_date>
  <completion_date type="Actual">April 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 25, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative shivering grade</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>&quot;grading of shivering,&quot; in which shivering degree was assessed as 1 of 5 levels (0, 1, 2, 3, and 4), grade 0 lack of shivering, grade 1 slight shivering (inconsiderable yet apparent peripheral vasoconstriction), grade 2 medium level shivering (muscular activity in one muscle group only) grade 3 severe shivering (muscular activity in more than one muscle group without generalized shivering) and grade 4 generalized shivering.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shivering frequency</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>Number of shivering episodes in postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss volume</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>Assessing blood loss in surgical drains postoperative</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Shivering Control</condition>
  <arm_group>
    <arm_group_label>aminoacid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received an IV amino acid infusion 150 ml/kg/hr starting just before and during anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>magnesium sulfate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received an IV magnesium sulphate bolus and infusion 40 mg/kg starting just before and during anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminoacid</intervention_name>
    <description>amino acid infusion 150 ml/kg/hr starting preoperative</description>
    <arm_group_label>aminoacid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>magnesium sulphate bolus and infusion 60 mg/kg starting preoperative</description>
    <arm_group_label>magnesium sulfate group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I-II who were listed for elective percutaneous nephrolithotomy PCNL surgery under&#xD;
             general anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic inefficiency&#xD;
&#xD;
          -  Renal inefficiency&#xD;
&#xD;
          -  Spinal anesthesia because of a different mechanism of hypothermia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 3, 2021</study_first_submitted>
  <study_first_submitted_qc>January 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Makram Soliman</investigator_full_name>
    <investigator_title>lecturer of anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

